Haselmeier said today that it entered into an exclusive agreement with Stevanato Group to license the Axis-D pen injector and intellectual property for the development, manufacturing and supply of the device for diabetes care.
Haselmeier’s Axis-D auto-injector pen is approved for use by the European Medical Agency and the FDA, among other regulatory bodies. The Zurich-based company said its pens are designed to be convenient, precise in dosing and enable an enhanced patient experience to support therapy efficiency.
Get the full story at our sister site, Drug Delivery Business News.